Marijke Eurelings
Meppel, DR, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Treatment satisfaction during personalized extended interval dosing of natalizumab in patients with multiple sclerosis.
Journal: Multiple sclerosis and related disorders
Published: April 30, 2026
Individual Variability of CD19+ B-Cell Repopulation in People With Multiple Sclerosis Treated With Extended Interval Dosing of Ocrelizumab.
Journal: European journal of neurology
Published: March 19, 2026
Low natalizumab trough concentrations are associated with reduced seroconversion of the John Cunningham virus in natalizumab-treated patients with multiple sclerosis.
Journal: Journal of neurology, neurosurgery, and psychiatry
Published: December 31, 2024
Serum neurofilament light and glial fibrillary acidic protein levels are not associated with wearing-off symptoms in natalizumab-treated multiple sclerosis patients.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: November 04, 2024
Influence of personalized extended interval dosing on the natalizumab wearing-off effect - a sub-study of the NEXT-MS trial.
Journal: Journal of the neurological sciences
Published: March 15, 2024
Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS).
Journal: Journal of neurology, neurosurgery, and psychiatry
Published: June 29, 2023
The magnitude of neurotoxicity in patients with multiple myeloma and the impact of dose modifications: results from the population-based PROFILES registry.
Journal: Annals of hematology
Published: June 21, 2016
Chemotherapy-induced neuropathy in multiple myeloma: influence on quality of life and development of a questionnaire to compose common toxicity criteria grading for use in daily clinical practice.
Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Published: July 03, 2015
Prevalence, specificity and functionality of anti-ganglioside antibodies in neuropathy associated with IgM monoclonal gammopathy.
Journal: Journal of neuroimmunology
Published: November 26, 2013
Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS).
Journal: European journal of cancer (Oxford, England : 1990)
Published: January 11, 2013
The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: August 23, 2012
Modifying the Medical Research Council grading system through Rasch analyses.
Journal: Brain : a journal of neurology
Published: December 23, 2011
Showing 1-12 of 12
Last Updated: 09/26/2026